Key result
New oral anticoagulants, which target factor Xa or thrombin, have distinct pharmacologic and clinical features compared to warfarin that can guide clinicians in selecting the right anticoagulant.
Why the study?
How do new oral anticoagulants compare to warfarin in terms of pharmacology, class effects, and clinical indications?
How do new oral anticoagulants compare to warfarin in terms of pharmacology, class effects, and clinical indications?
This review provides a comparative overview of new oral anticoagulants versus warfarin to assist clinicians in selecting the appropriate anticoagulant for individual patients.
Answers are grounded in this paper and cite their sources.
Guides NOAC selection versus warfarin in practice; leaves open need for ongoing comparative effectiveness research.
The new oral anticoagulants are rapidly replacing warfarin for several indications. In contrast to warfarin, which lowers the functional levels of all of the vitamin K-dependent clotting factors, the new agents target either factor Xa or thrombin. With targeted inhibition of coagulation, the new oral anticoagulants have pharmacologic and clinical features that distinguish them from warfarin. Focusing on these features, this paper (a) compares the pharmacology of the new oral anticoagulants with that of warfarin (b) identifies the class effects of these drugs and their differentiating features, (c) reviews their current indications, and (d) uses this information to help clinicians make informed decisions regarding the choice of the right anticoagulant for the right patient.
No takes yet. Share an insight, caveat, or question.
Weitz et al. (2012) conducted a review in Indications for anticoagulation. New oral anticoagulants vs. Warfarin was evaluated. New oral anticoagulants, which target factor Xa or thrombin, have distinct pharmacologic and clinical features compared to warfarin that can guide clinicians in selecting the right anticoagulant.
Synapse has enriched 10 related papers. Consider them for comparative context: